Ubs Group Ag Codiak Bio Sciences, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$0.32 - $0.9 $50 - $143	-159 Reduced 63.6%	91 $0
Q3 2022 Nov 10, 2022	SELL	$0.82 - $3.19 $300 - $1,167	-366 Reduced 59.42%	250 $0
Q2 2022 Aug 10, 2022	BUY	$2.24 - $6.96 $1,379 - $4,287	616 New	616 $2,000
Q1 2022 May 16, 2022	SELL	$4.3 - $12.95 $16,004 - $48,199	-3,722 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.0 - $16.78 $18,780 - $31,512	-1,878 Reduced 33.54%	3,722 $41,000
Q3 2021 Nov 15, 2021	SELL	$15.58 - $22.88 $29,602 - $43,472	-1,900 Reduced 25.33%	5,600 $91,000
Q2 2021 Aug 13, 2021	SELL	$11.72 - $26.81 $2,953 - $6,756	-252 Reduced 3.25%	7,500 $139,000
Q1 2021 May 12, 2021	SELL	$13.49 - $31.53 $11,210 - $26,201	-831 Reduced 9.68%	7,752 $116,000
Q4 2020 Feb 11, 2021	BUY	$7.9 - $32.3 $67,805 - $277,230	8,583 New	8,583 $278,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.